Table 2 Galectin-3 and sST2 levels in various subgroups of the study population

Female patients (n = 36; 90%)

13.2 ± 4.1

27.3 ± 9.8

Male patients (n = 4; 10%)

9.6 ± 0.2

40.1 ± 18.7

Limited cutaneous form (n = 12; 30%)

12.9 ± 3.1

30.1 ± 9.5

Diffuse cutaneous form (n = 28; 70%)

12.9 ± 4.4

27.9 ± 12.1

Anti-centromere antibody positive (n = 8; 20%)

11.3 ± 2.8

28.6 ± 9.4

Anti-centromere antibody negative (n = 32; 80%)

13.0 ± 4.1

29.1 ± 11.8

Anti-topoisomerase antibody positive (n = 19; 47.5%)

12.8 ± 4.5

27.0 ± 8.6

Anti-topoisomerase antibody negative (n = 21; 52.5%)

12.8 ± 3.7

29.5 ± 13.6

Patients with diabetes (n = 2; 5%)

13.4 ± 6.3

36.5 ± 15.2

Patients without diabetes (n = 38; 95%)

12.8 ± 4.0

28.1 ± 11.2

Current smokers (n = 3; 7.5%)

11.5 ± 5.5

30.7 ± 27.4

Non-smokers (n = 37; 92.5%)

13.1 ± 3.8

26.9 ± 9.4

Hypertension (n = 25; 62.5%)

13.3 ± 3.9

26.9 ± 9.6

No hypertension (n = 15; 37.5%)

12.2 ± 4.3

31.2 ± 13.6

Treated with angiotensin convertase enzyme inhibitors (n = 12; 30%)

14.1 ± 3.6

26.6 ± 9.0

Not treated with angiotensin convertase enzyme inhibitors (n = 28; 70%)

12.3 ± 4.1

28.4 ± 12.0

Treated with calcium channel blockers (n = 18; 45%)

12.8 ± 3.6

27.1 ± 10.3

Not treated with calcium channel blockers (n = 22; 55%)

12.9 ± 4.4

29.7 ± 12.2

Treated with loop diuretics (n = 12; 30%)

15.5 ± 3.8

25.5 ± 7.9

Not treated with loop diuretics (n = 28; 70%)

11.7 ± 3.6

29.8 ± 12.4

Treated with mineralocorticoid receptor antagonists (n = 10; 25%)

13.5 ± 4.3

29.7 ± 10.5

Not treated with mineralocorticoid receptor antagonists (n = 30; 75%)

12.7 ± 4.0

28.1 ± 11.7

Treated with pentoxifylline (n = 20; 50%)

12.8 ± 3.6

28.4 ± 11.3

Not treated with pentoxifylline (n = 20;50%)

12.9 ± 4.5

28.7 ± 11.6